Objectives: To test four 16-membered macrolides ( josamycin, spiramycin, midecamycin and rokitamycin) along with other compounds in the same class (erythromycin, clarithromycin, roxithromycin and azithromycin) plus clindamycin and telithromycin, against Streptococcus pyogenes and Streptococcus pneumoniae isolates with well-characterized resistance genotypes.
Introduction
Since the early 1990s, a dramatic increase in the isolation of erythromycin-resistant streptococci has been observed worldwide, some of the highest prevalence values being reported in Italy. 1 -3 The precise implications for clinical outcomes of the different resistance phenotypes need to be fully elucidated, also with a view to the possibility of both testing and using alternative compounds in the same class.
Data regarding susceptibility to 16-membered macrolides are few and far between, often involving a limited number of compounds and suggesting heterogeneous susceptibility patterns. This prompted us to test four 16-membered macrolides, along with other compounds in the same class and clindamycin and telithromycin, against a substantial number of Streptococcus pyogenes and Streptococcus pneumoniae isolates representative of different Italian geographical areas and well-characterized with regard to their resistance genotype.
Materials and methods
Four hundred and eighty-six isolates of S. pyogenes and 375 isolates of S. pneumoniae were tested for their susceptibility to four 16-membered macrolides ( josamycin, spiramycin, midecamycin and rokitamycin), three 14-membered macrolides (erythromycin, clarithromycin and roxithromycin), the 15-membered azalide azithromycin, the lincosamide clindamycin and the ketolide telithromycin.
All strains had been isolated over the period 2002-2003 from specimens of different human origin (92% throat swabs and the others being from either blood or wound exudates) obtained in different geographical areas and from patients of different ages.
MICs were determined by agar dilution on Mueller -Hinton plates supplemented with 5% sheep blood and inoculated with 10 4 -10 5 cfu/mL using a Steer inoculator. The plates were incubated overnight at 358C with 5% CO 2 . S. pneumoniae ATCC 49619 was used as a control strain. Interpretation of the results was basically as outlined in the latest CLSI (formerly NCCLS) guidelines. 4 When CLSI breakpoints were not available, the results were interpreted according to either the breakpoints proposed by the French Society for Microbiology (telithromycin, roxithromycin, josamycin, spiramycin and midecamycin) 5 or those published by Ono et al. 6 (rokitamycin).
The resistance phenotype was determined by the double disc test with erythromycin and clindamycin as described previously. 7 The presence of resistance genes was determined by PCR amplification, as described by Daly et al. 8 PCR primers for mef(E), mef(A), erm(A) and erm(B) were designed to provide specific PCR products of 363, 553, 590 and 764 bp, respectively. The mef(E) primers were as described by Daly et al. 8 (5 0 -GGG AGA TGA AAA GAA GGA GT-3 0 and 5 0 -TAA AAT GGC ACC GAA AG-3 0 ). The mef(A) primers were as described by Daly et al. Table 1 lists the MICs and interpretative categories for S. pyogenes and S. pneumoniae. One hundred and fifty-two S. pyogenes isolates (31.3% of the total) were erythromycin-resistant. All of the erythromycin-resistant strains were also resistant to clarithromycin, azithromycin and roxithromycin. Forty-eight isolates (9.9% of the total) proved non-susceptible to clindamycin. The number of isolates non-susceptible to 16-membered macrolides ranged from 78 (rokitamycin, 16% of the total) to 95 (midecamycin, 19.5% of the total). Four hundred and fifty-seven isolates 
Results

Discussion
Resistance to 14-and 15-membered macrolides commonly used in clinical practice could be theoretically overcome by employing 'diverse' macrolides, such as 16-membered compounds and telithromycin.
Although telithromycin has been clearly shown to be active against most streptococcal strains, irrespective of their erythromycin susceptibility, data regarding 16-membered compounds are few and far between, often collected on the occasion of specific outbreaks only and limited to the compounds used in those specific countries.
All of the M isolates and 65% of the iMLS B isolates (but none of the cMLS B isolates) were susceptible to the 16-membered compound miokamycin in the Finnish outbreak, 7 and all of the M isolates and roughly 50% of the iMLS B isolates (but again none of the cMLS B isolates) were susceptible to another 16-membered compound, namely josamycin, in a survey carried out during the Italian outbreak. 9 In another Italian survey, only the iMLS B isolates with erm(A) presented a definite zone of inhibition around the josamycin or spiramycin discs in the agar diffusion test.
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Consistent with those partial reports, our results showed that all four 16-membered macrolides we tested were generally active against M-type isolates of S. pyogenes (MIC 50 s and MIC 90 s, 0.06 to 0.5 mg/L), but not against the cMLS B isolates (MIC 50 s, 256 mg/L). As regards the iMLS B isolates, the susceptibility values were distinctly lower in the isolates with erm(A) (ranging from 0.06 to 0.5 mg/L) than in those with erm(B) (ranging from 0.12 to 256 mg/L). Against pneumococcal isolates too, all 16-membered macrolides tested showed very good activity against the M-type erythromycin-resistant isolates, with a wide activity range (0.06 to 4 mg/L) against the iMLS B isolates even though only erm(B) isolates were represented.
Most S. pyogenes and S. pneumoniae isolates examined in the present study (94.0% and 99.7%, respectively) were susceptible to telithromycin, but the susceptibility values for the M-type erythromycin-resistant isolates (MIC 90 s, 0.5 mg/L) were at least four times higher than for the erythromycin-susceptible ones (and for most of the erythromycin-resistant MLS B isolates, too), which has been shown to be related to telithromycin acting as a substrate for an efflux pump. 11, 12 Despite the fair in vitro activity of some compounds, most notably rokitamycin, any clinical use against iMLS B streptococci should be regarded with the utmost caution, also on the basis of previous experience with 'dissociated' erythromycin resistance in staphylococcal strains, whose in vitro susceptibility to noninducing 16-membered macrolides proved to be illusory in the clinical setting because of the ease with which mutants constitutively resistant to all MLS B antibiotics arose as a consequence of nucleotide sequence alterations. 13 Moreover, the virtual absence of widely accepted and internationally validated breakpoints for 16-membered macrolides often makes it difficult to translate their in vitro activity into precise clinical recommendations and to evaluate the correlation between these susceptibility results and those obtained for 
